Skip to main
LIVN

Livanova (LIVN) Stock Forecast & Price Target

Livanova (LIVN) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 50%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

LivaNova's revenue for 2024 is projected to grow significantly, with management guiding sales expectations between $940 million and $955 million, building on a previous growth of 29% to $803 million. Additionally, the company is forecasting positive scenarios for its aura6000 product, anticipating potential market share increases leading to sales of $120 million in 2027 and $280 million by 2029. This strong sales outlook, combined with a focus on specialized cardiopulmonary and neuromodulation devices, supports a favorable financial trajectory for LivaNova.

Bears say

LivaNova's stock outlook is negatively impacted by anticipated revenue growth slowing to the low-single digits, primarily due to ongoing challenges in its Neuromodulation and Cardiovascular segments. Additionally, the company faces operational margin contraction and is projected to deliver earnings that fall below consensus expectations. Key risks further complicate LivaNova's situation, including the potential failure to secure FDA approval for its aura6000 device and slower-than-expected growth in its core Neuromodulation and Cardiopulmonary businesses.

Livanova (LIVN) has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 50% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Livanova and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Livanova (LIVN) Forecast

Analysts have given Livanova (LIVN) a Buy based on their latest research and market trends.

According to 8 analysts, Livanova (LIVN) has a Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $65, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $65, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Livanova (LIVN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.